Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Front-Line Of Melanoma Market Could Be Marketing Battle

Executive Summary

Roche's vemurafenib and Bristol-Myers Squibb's Yervoy (ipilimumab) are most likely synergistic treatments for metastatic melanoma that can be used in combination or sequentially. But in certain front-line patients, there could be a struggle between the two different therapeutic options.

You may also be interested in...

PD-1 Progress May Shorten The Life Of Other Drugs

With PD-1 immunotherapy continuing to make gains in melanoma, will Yervoy and targeted BRAF/MEK combos from Novartis, Roche and Array BioPharma get relegated to second-class status?

Oncologists Audition Yervoy And Zelboraf For First-line Roles, With New Combos In Near Sight

Cooperative group plans trial testing Yervoy vs. Zelboraf in first-line metastatic melanoma to help settle the issue of which therapy should come first in BRAF-mutation positive patients. New therapies on the way promise to further complicate decision-making.

Oncologists Embrace BRAF Testing, Coast Through Managed Care With New Melanoma Drugs

Six-figure pricing in oncology is becoming increasingly common and has raised eyebrows, but a new survey of new melanoma drugs Yervoy and Zelboraf suggests that so far high price is not an obstacle to adoption. So soon after launch, it’s still unclear if one treatment will emerge dominant in first-line treatment.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts